123 related articles for article (PubMed ID: 27152444)
1. Immunohistochemical evaluation of p16 expression in cutaneous histiocytic, fibrohistiocytic and undifferentiated lesions.
Smith EH; Lowe L; Harms PW; Fullen DR; Chan MP
J Cutan Pathol; 2016 Aug; 43(8):671-8. PubMed ID: 27152444
[TBL] [Abstract][Full Text] [Related]
2. Loss of p16 expression and copy number changes of CDKN2A in a spectrum of spitzoid melanocytic lesions.
Harms PW; Hocker TL; Zhao L; Chan MP; Andea AA; Wang M; Harms KL; Wang ML; Carskadon S; Palanisamy N; Fullen DR
Hum Pathol; 2016 Dec; 58():152-160. PubMed ID: 27569296
[TBL] [Abstract][Full Text] [Related]
3. Microphthalmia-associated transcription factor (MiTF): Promiscuous staining patterns in fibrohistiocytic lesions is a potential pitfall.
Mohanty SK; Sharma S; Pradhan D; Kandukuri SR; Farahani N; Barry C; Wu JM; Frishberg D; Balzer B
Pathol Res Pract; 2018 Jun; 214(6):821-825. PubMed ID: 29773427
[TBL] [Abstract][Full Text] [Related]
4. Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses.
Shin J; Vincent JG; Cuda JD; Xu H; Kang S; Kim J; Taube JM
J Am Acad Dermatol; 2012 Oct; 67(4):717-26. PubMed ID: 22325460
[TBL] [Abstract][Full Text] [Related]
5. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
Hanly AJ; Jordà M; Elgart GW; Badiavas E; Nassiri M; Nadji M
Arch Pathol Lab Med; 2006 Jun; 130(6):831-4. PubMed ID: 16740036
[TBL] [Abstract][Full Text] [Related]
6. Protein gene product 9.5 (PGP9.5) expression in benign cutaneous mesenchymal, histiocytic, and melanocytic lesions: comparison with cellular neurothekeoma.
Wang GY; Nazarian RM; Zhao L; Hristov AC; Patel RM; Fullen DR; Chan MP
Pathology; 2017 Jan; 49(1):44-49. PubMed ID: 27914685
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of CD163 in cutaneous spindle cell lesions.
Pouryazdanparast P; Yu L; Cutlan JE; Olsen SH; Fullen DR; Ma L
J Cutan Pathol; 2009 Aug; 36(8):859-64. PubMed ID: 19040468
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans.
Lisovsky M; Hoang MP; Dresser KA; Kapur P; Bhawan J; Mahalingam M
Mod Pathol; 2008 Jan; 21(1):31-8. PubMed ID: 17885669
[TBL] [Abstract][Full Text] [Related]
9. Expression of p16 alone does not differentiate between Spitz nevi and Spitzoid melanoma.
Mason A; Wititsuwannakul J; Klump VR; Lott J; Lazova R
J Cutan Pathol; 2012 Dec; 39(12):1062-74. PubMed ID: 23005921
[TBL] [Abstract][Full Text] [Related]
10. The Amount of Melanin Influences p16 Loss in Spitzoid Melanocytic Lesions: Correlation With CDKN2A Status by FISH and MLPA.
Martinez Ciarpaglini C; Gonzalez J; Sanchez B; Agusti J; Navarro L; Nieto G; Monteagudo C
Appl Immunohistochem Mol Morphol; 2019 Jul; 27(6):423-429. PubMed ID: 29489509
[TBL] [Abstract][Full Text] [Related]
11. [Fibrohistiocytic skin tumors].
Hügel H
J Dtsch Dermatol Ges; 2006 Jul; 4(7):544-55. PubMed ID: 16827912
[TBL] [Abstract][Full Text] [Related]
12. Reticulohistiocytoma (solitary epithelioid histiocytoma): a clinicopathologic and immunohistochemical study of 44 cases.
Miettinen M; Fetsch JF
Am J Surg Pathol; 2006 Apr; 30(4):521-8. PubMed ID: 16625100
[TBL] [Abstract][Full Text] [Related]
13. Tenascin expression in cutaneous fibrohistiocytic tumors. Immunohistochemical investigation of 24 cases.
Franchi A; Santucci M
Am J Dermatopathol; 1996 Oct; 18(5):454-9. PubMed ID: 8902090
[TBL] [Abstract][Full Text] [Related]
14. The effect of the sun on expression of beta-catenin, p16 and cyclin d1 proteins in melanocytic lesions.
Demirkan NC; Kesen Z; Akdag B; Larue L; Delmas V
Clin Exp Dermatol; 2007 Nov; 32(6):733-9. PubMed ID: 17868395
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of ERG immunostaining in dermatofibroma.
Yamada Y; Ichiki T; Susuki Y; Yamada-Nozaki Y; Tateishi Y; Furue M; Oda Y
J Clin Pathol; 2023 Aug; 76(8):536-540. PubMed ID: 35318257
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of p16 protein expression and CDKN2A deletion in conventional and fibrosarcomatous dermatofibrosarcoma protuberans.
Siref A; Patel V; Reith JD; Balzer BL; Shon W
Pathology; 2018 Jun; 50(4):474-475. PubMed ID: 29743142
[No Abstract] [Full Text] [Related]
17. Could cathepsin-k be a driver of the myofibroblastic differentiation observed in dermatofibroma, atypical fibroxanthoma and pleomorphic dermal sarcoma?
Ricci C; De Leo A; Dika E; Lambertini M; Veronesi G; Corti B
Acta Histochem; 2020 Feb; 122(2):151498. PubMed ID: 31889532
[TBL] [Abstract][Full Text] [Related]
18. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma.
Lazova R; Moynes R; May D; Scott G
Cancer; 1997 Jun; 79(11):2115-24. PubMed ID: 9179057
[TBL] [Abstract][Full Text] [Related]
19. Another point of view on p16 and Ki67 expression in melanocytic and non-melanocytic cutaneous lesions.
Donati P; Paolino G; Panetta C; Cota C; Zaccarini M; Muscardin L
Acta Dermatovenerol Croat; 2013; 21(3):149-54. PubMed ID: 24183217
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical observation of intracytoplasmic lysozyme in proliferative and neoplastic fibrohistiocytic lesions.
Nakanishi S; Shinomiya S; Sano T; Hizawa K
Acta Pathol Jpn; 1982 Nov; 32(6):949-59. PubMed ID: 6297236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
